Minerva Neurosciences, Inc.
NASDAQ:NERVBiotechnology
-$0.30 today
- Market cap
- $108.64M
- Beta
- -0.11
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$8.46
Volume 0.28M
Average 0.21M
NERV Total Non-current Liabilities
All obligations due after more than one year.
Minerva Neurosciences, Inc.NASDAQ: NERV
Total Non-current Liabilities · Q2 FY2026 · quarter ended Jun 2026
Total non-current liabilities rises 487717.0% from a year ago
Total non-current liabilities stood at $292.69B at the end of Q2 FY2026, up 487717.0% from a year earlier and up 85093.6% from the prior quarter. Over 3 fiscal years it compounded at +47.5% a year.
Context
- Total non-current liabilities amounted to 307.8% of total assets at the end of Q2 FY2026, up 110.6 pp from a year earlier.
- Total non-current liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total non-current liabilities keeps rising in the next quarterly balance sheet after a +487717.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $292.69B+85093.6% QoQ
- Last fiscal yearDec 2025
- $236.43M+294.0% YoY
- Year agoJun 2025
- $60M+487717.0% since
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 236.43M USD
- Year-over-year change
- +294.0%
- 4-year CAGR
- +37.4%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 236.43M | +294.0% |
| FY2024 | 2024-12-31 | 60M | -26.8% |
| FY2023 | 2023-12-31 | 82.02M | +11.2% |
| FY2022 | 2022-12-31 | 73.73M | +11.2% |
| FY2021 | 2021-12-31 | 66.33M | — |
Total Non-current Liabilities vs competitors
How NERV compares with its peers on the latest reported figures
- NERV's Jun 2026 total non-current liabilities of $292.69B is the highest of the 4 companies compared; the peer median is $184K.
- Its year-over-year change of +487717.0% is the highest of 3, against a peer median of +63965.4%.
- Total non-current liabilities amounts to 307.8% of total assets for NERV, versus a peer median of 2.1%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Jun 2026 | $292.69B | +487717.0% | +47.5% | 307.8% | |
| Dec 2025 | $383.03M | +128003.3% | +350.3% | 16.5% | |
NRXSNeurAxis, Inc. | Mar 2026 | $184K | -72.5% | +40.8% | 2.1% |
| Mar 2026 | $55K | — | -39.7% | 0.1% | |
| Peer median (excluding NERV) | $184K | +63965.4% | +40.8% | 2.1% | |
Competitors are the stored peer set for NERV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Cash & Equivalents | 60.76M | 36.09M | 40.91M | 21.36M | 82.3M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Other Current Assets | 100K | 4.07M | 1.09M | 906.9K | 798K |
| Total Current Assets | 62.2M | 40.16M | 42M | 22.27M | 83.1M |
| Property, Plant & Equipment (Net) | 51.08K | 16.33K | 10.88K | 5.44K | 0 |
| Goodwill | 14.87M | 14.87M | 14.87M | 14.87M | 14.87M |
| Intangible Assets | 0 | 42.57K | 17.03K | 0 | 0 |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | (1) | 0 | 0 | 0 | 0 |
| Total Non-current Assets | 14.92M | 14.93M | 14.9M | 14.87M | 14.87M |
| Total Assets | 77.12M | 55.09M | 56.9M | 37.14M | 97.97M |
| Account Payables | 1.85M | 969.67K | 1.81M | 1.61M | 639K |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 0 | 14.83K | 590.77K | 363.18K | (473) |
| Total Current Liabilities | 2.82M | 1.38M | 3.34M | 2.84M | 2.29M |
| Long-term Debt | 0 | 0 | 0 | 0 | 64.96M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 66.33M | 73.73M | 82.02M | 60M | 171.46M |
| Total Non-current Liabilities | 66.33M | 73.73M | 82.02M | 60M | 236.43M |
| Total Liabilities | 69.15M | 75.11M | 85.36M | 62.84M | 238.72M |
| Common Stock | 534 | 534 | 699 | 699 | 4.33K |
| Retained Earnings | (334.7M) | (366.81M) | (396.82M) | (395.38M) | (688.8M) |
| Accumulated OCI | 0 | 0 | 0 | 0 | 0 |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 7.98M | (20.02M) | (28.46M) | (25.69M) | (140.75M) |
| Total Debt | 0 | 0 | 0 | 0 | 64.96M |
| Net Debt | (60.76M) | (36.09M) | (40.91M) | (21.36M) | (17.34M) |
Minerva Neurosciences, Inc.
NASDAQ:NERV
Intrinsic Alpha fair value
Locked
Current Price
$2.18
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.